26171-23-3
26171-23-3 結(jié)構(gòu)式
基本信息
痛滅定
托麥汀
托美汀
2-[1-甲基-5-(4-甲基苯甲酰)吡咯-2-基]乙酸
Tolmetine
TOLMETINUM
2-[1-Methyl-5-(4-methylbenzoyl)-pyrrol-2-yl]acetic acid
1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-
1-Methyl-5-p-toluoylpyrrole-2-acetic acid
5-[(p-Tolyl)carbonyl]-1-methylpyrrole-2-acetic acid
McN 2559
1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid
1-Methyl-5-(p-toluoyl)-1H-pyrrole-2-acetic acid
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問題列表
|
Human COX-1 0.35 μM (IC 50 ) |
Human COX-2 0.82 μM (IC 50 ) |
Tolmetin (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat.
Tolmetin (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner.
Tolmetin (0-100 μM) shows no effect on osteoblast growth.
Tolmetin (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg.
Tolmetin (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity.